Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Rivaroxaban or aspirin for extended treatment of VTE

TITLE: Low-dose or full-dose rivaroxaban is superior to aspirin for long-term anticoagulation

CLINICAL QUESTION: Is full or lower intensity rivaroxaban better for extended treatment of venous thromboembolism (VTE) as compared to aspirin?

BACKGROUND: Various medications are used for long-term anticoagulation therapy for VTE, however the treatments available are commonly complex, expensive or require monitoring. With the development of direct oral anticoagulants (DOACs), optimal regimens, especially for long-term management of VTE are unclear.

STUDY DESIGN: Multicenter randomized double-blinded phase III trial.

SETTING: 230 Medical centers worldwide in 20 countries.

SYNOPSIS: 3,365 patients with a history of VTE who had undergone 6-12 months of initial anticoagulation therapy and in whom continuation of therapy was thought to be beneficial were enrolled. Patients were randomly assigned to daily high-dose rivaroxaban (20 mg) or daily low-dose rivaroxaban (10 mg) or aspirin (100 mg). After a median of 351 days, symptomatic recurrent VTE or unexplained death occurred in 17 of the 1,107 patients (1.5%) who were assigned to the high-dose group, in 13 of 1,127 patients (1.2%) who were assigned to the low-dose group, and in 50 of 1,131 patients (4.4%) who were assigned to aspirin. Bleeding rates were not significantly different between the three groups (2%-3%). The major limitation of this study is the short duration of follow-up and the lack of power to demonstrate noninferiority of the low-dose as compared to the high-dose regimen for rivaroxaban.

BOTTOM LINE: In patients with a history of VTE, in whom prolonged anticoagulation could be beneficial, low or high-dose rivaroxaban is superior to aspirin in preventing recurrent VTE without increasing bleeding risk.

CITATION: Weitz JI, Lensing MH, Prins R, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017; 376:1211-22.

Dr. Mayasy is assistant professor in the department of hospital medicine at the University of New Mexico.

  • 1

    Rivaroxaban or aspirin for extended treatment of VTE

    July 21, 2017

  • 1

    Corticosteroid therapy in Kawasaki disease

    July 20, 2017

  • 1

    Pediatric hospital medicine marches toward subspecialty recognition

    July 19, 2017

  • 1

    Hospitalizations may speed up cognitive decline in older adults

    July 19, 2017

  • New tool predicts antimicrobial resistance in sepsis

    July 19, 2017

  • 1

    Study: No increased mortality with ACA-prompted readmission declines

    July 18, 2017

  • 1

    High Value Care curriculum reduced echocardiogram ordering

    July 18, 2017

  • 1

    What is the best approach for managing CIED infections?

    July 17, 2017

  • 1

    Plasma biomarker distinguishes ARDS, acute heart failure

    July 15, 2017

  • 1

    The role of NPs and PAs in hospital medicine programs

    July 14, 2017

1 … 447 448 449 450 451 … 967
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences